menu
    • menu
    [{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Apraclonidine Hydrochloride","moa":"Adrenergic receptor alpha-2A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow Health","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Harrow Health"},{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harrow Health Announces Launch of IOPIDINE\u00ae 1% and MAXITROL\u00ae in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Apraclonidine Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Harrow \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Not Applicable"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Marketing Authorisations for IOPIDINE\u00ae (apraclonidine) Fully Transferred to Essential Pharma as Change in UK NICE Guidelines for Glaucoma Treatment Expected to Lead to Increase in Patients\u2019 Need for Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Apraclonidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Essential Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essential Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Essential Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"French Marketing Authorization for Iopidine\u00ae 1% (Apraclodinin) Transferred to Essential Pharma in Line with The Company's Medical Needs and Expansion Strategy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Apraclonidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Essential Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Essential Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Essential Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Essential Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essential Pharma Expands Global Portfolio with Ocular and Postpartum Acquisitions","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Apraclonidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Essential Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Apraclonidine Hydrochloride

    Menu

    Apraclonidine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Essential Pharma

                            United Kingdom arrow
                            Luxepack
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            French Marketing Authorization for Iopidine® 1% (Apraclodinin) Transferred to Essential Pharma in Line with T...

                            Details : Iopidine (apraclonidine hydrochloride), is an alpha2-adrenergic agonist, a sympathomimetic used in glaucoma therapy. It is used as a short-term adjunctive therapy in open-angle glaucoma who are on maximally tolerated medical therapy requiring additional ...

                            Brand Name : Iopidine

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 16, 2023

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Essential Pharma

                            United Kingdom arrow
                            Luxepack
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            UK Marketing Authorisations for IOPIDINE® (apraclonidine) Fully Transferred to Essential Pharma as Change in ...

                            Details : IOPIDINE (apraclonidine hydrochloride), is a short-term adjunctive therapy for chronic glaucoma to prevent or control intraocular pressure including after selective laser therapy, a form of laser eye surgery now recommended as the initial treatment for o...

                            Brand Name : Iopidine

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 15, 2022

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Harrow

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States

                            Details : IOPIDINE 1% Ophthalmic Solution contains apraclonidine hydrochloride, an alpha-adrenergic agonist, in a sterile isotonic solution for topical application to the eye.

                            Brand Name : Iopidine

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 24, 2022

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Luxepack
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Harrow

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops

                            Details : FDA-approved IOPIDINE 1% is the gold standard for treating or preventing intraocular pressure during and after YAG laser eye surgery, which is required for about 40% of all prior cataract surgery patients.

                            Brand Name : Iopidine

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 20, 2021

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Harrow

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Luxepack
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Essential Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Essential Pharma Expands Global Portfolio with Ocular and Postpartum Acquisitions

                            Details : Essential pharma acquires Iopidine (apraclonidine hydrochloride), is an alpha2-adrenergic agonist, for the adjunctive treatment of glaucoma and Methergine for treating post-partum haemorrhage.

                            Brand Name : Iopidine

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 16, 2021

                            Lead Product(s) : Apraclonidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Essential Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth